ICD-10-CM D68: Other coagulation defects

abnormal coagulation profile NOS (R79.1)

• capillary fragility (hereditary) (D69.8)
• factor VIII deficiency NOS (D66)
• factor VIII deficiency with functional defect (D66)

• antiphospholipid antibody, finding without diagnosis (R76.0)
• antiphospholipid antibody syndrome (D68.61)
• antiphospholipid antibody with hypercoagulable state (D68.61)
• lupus anticoagulant (LAC) finding without diagnosis (R76.0)
• lupus anticoagulant (LAC) with hypercoagulable state (D68.62)
• systemic lupus erythematosus [SLE] inhibitor finding without diagnosis (R76.0)
• systemic lupus erythematosus [SLE] inhibitor with hypercoagulable state (D68.62)

vitamin K deficiency of newborn (P53)

• antiphospholipid syndrome (D68.61)
• lupus anticoagulant (D68.62)
• secondary activated protein C resistance (D68.69)
• secondary antiphospholipid antibody syndrome (D68.69)
• secondary lupus anticoagulant with hypercoagulable state (D68.69)
• secondary systemic lupus erythematosus [SLE] inhibitor with hypercoagulable state (D68.69)
• systemic lupus erythematosus [SLE] inhibitor finding without diagnosis (R76.0)
• systemic lupus erythematosus [SLE] inhibitor with hemorrhagic disorder (D68.312)
• thrombotic thrombocytopenic purpura (M31.19)

• diffuse or disseminated intravascular coagulation [DIC] (D65)
• heparin induced thrombocytopenia (HIT) (D75.82-)
• hyperhomocysteinemia (E72.11)

• anti-phospholipid antibody, finding without diagnosis (R76.0)
• anti-phospholipid antibody with hemorrhagic disorder (D68.312)
• lupus anticoagulant syndrome (D68.62)

• anticardiolipin syndrome (D68.61)
• antiphospholipid syndrome (D68.61)
• lupus anticoagulant (LAC) finding without diagnosis (R76.0)
• lupus anticoagulant (LAC) with hemorrhagic disorder (D68.312)

hemorrhagic disease of newborn (P53)

• coagulation defects complicating abortion or ectopic or molar pregnancy (O00-O07, O08.1)
• coagulation defects complicating pregnancy, childbirth and the puerperium (O45.0, O46.0, O67.0, O72.3)

code for adverse effect, if applicable, to identify drug (T45.515, T45.525)

• Partial quantitative deficiency of von Willebrand factor
• Type 1C von Willebrand disease

Qualitative defects of von Willebrand factor

Qualitative defects of von Willebrand factor with decreased platelet adhesion and selective deficiency of high-molecular-weight multimers

• Qualitative defects of von Willebrand factor with high-molecular-weight von Willebrand factor loss
• Qualitative defects of von Willebrand factor with hyper-adhesive forms
• Qualitative defects of von Willebrand factor with increased affinity for platelet glycoprotein lb

Qualitative defects of von Willebrand factor with defective platelet adhesion with a normal size distribution of von Willebrand factor multimers

• Qualitative defects of von Willebrand factor with defective von Willebrand factor to factor VIII binding
• Qualitative defects of von Willebrand factor with markedly decreased affinity for factor VIII

Qualitative defect in von Willebrand factor function, with no further subtyping

• (Near) complete absence of von Willebrand factor
• Total quantitative deficiency of von Willebrand factor

Acquired von Willebrand syndrome

• Platelet-type von Willebrand disease
• Pseudo-von Willebrand disease

• Hemophilia C
• Plasma thromboplastin antecedent [PTA] deficiency
• Rosenthal's disease

• AC globulin deficiency
• Congenital afibrinogenemia
• Deficiency of factor I [fibrinogen]
• Deficiency of factor II [prothrombin]
• Deficiency of factor V [labile]
• Deficiency of factor VII [stable]
• Deficiency of factor X [Stuart-Prower]
• Deficiency of factor XII [Hageman]
• Deficiency of factor XIII [fibrin stabilizing]
• Dysfibrinogenemia (congenital)
• Hypoproconvertinemia
• Owren's disease
• Proaccelerin deficiency

• Autoimmune hemophilia
• Autoimmune inhibitors to clotting factors
• Secondary hemophilia

• Lupus anticoagulant (LAC) with hemorrhagic disorder
• Systemic lupus erythematosus [SLE] inhibitor with hemorrhagic disorder

• Antithromboplastinemia
• Antithromboplastinogenemia
• Hemorrhagic disorder due to intrinsic increase in antithrombin
• Hemorrhagic disorder due to intrinsic increase in anti-VIIIa
• Hemorrhagic disorder due to intrinsic increase in anti-IXa
• Hemorrhagic disorder due to intrinsic increase in anti-XIa

• Drug-induced hemorrhagic disorder
• Hemorrhagic disorder due to increase in anti-IIa
• Hemorrhagic disorder due to increase in anti-Xa
• Hyperheparinemia

• Deficiency of coagulation factor due to liver disease
• Deficiency of coagulation factor due to vitamin K deficiency

Primary hypercoagulable states

Factor V Leiden mutation

• Antithrombin III deficiency
• Hypercoagulable state NOS
• Primary hypercoagulable state NEC
• Primary thrombophilia NEC
• Protein C deficiency
• Protein S deficiency
• Thrombophilia NOS

Other hypercoagulable states

• Anticardiolipin syndrome
• Antiphospholipid antibody syndrome

• Lupus anticoagulant
• Presence of systemic lupus erythematosus [SLE] inhibitor

• COVID-19 associated hypercoagulability
• Hypercoagulable states NEC
• Secondary hypercoagulable state NOS

COVID-19 associated coagulopathy

, if applicable, qualitative platelet defects (D69.1)

, if applicable, associated condition

, if applicable, associated condition